The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer

Detalhes bibliográficos
Autor(a) principal: De Mello, RA
Data de Publicação: 2020
Outros Autores: Neves, NM, Amaral, GA, Lippo, EG, Castelo Branco, P, Daniel Pozza, Tajima, CC, Antoniou, G
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/131718
Resumo: Introduction: Non-small cell lung cancer (NSCLC) is the second most common cancer globally. The mesenchymal-epithelial transition (MET) proto-oncogene can be targeted in NSCLC patients.Methods: We performed a literature search on PubMed in December 2019 for studies on MET inhibitors and NSCLC. Phase II and III clinical trials published in English between 2014 and 2019 were selected.Results: Data on MET inhibitors (tivantinib, cabozantinib, and crizotinib) and anti-MET antibodies (emibetuzumab and onartuzumab) are reported in the text.Conclusion: Emibetuzumab could be used for NSCLC cases with highMETexpression. Further, studies on onartuzumab failed to prove its efficacy, while the results of tivantinib trials were clinically but not statistically significant. Additionally, cabozantinib was effective, but adverse reactions were common, and crizotinib was generally well-tolerated.
id RCAP_637eaa90c6c678e89fdff093eac887ab
oai_identifier_str oai:repositorio-aberto.up.pt:10216/131718
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung CancerCiências da Saúde, Ciências médicas e da saúdeHealth sciences, Medical and Health sciencesIntroduction: Non-small cell lung cancer (NSCLC) is the second most common cancer globally. The mesenchymal-epithelial transition (MET) proto-oncogene can be targeted in NSCLC patients.Methods: We performed a literature search on PubMed in December 2019 for studies on MET inhibitors and NSCLC. Phase II and III clinical trials published in English between 2014 and 2019 were selected.Results: Data on MET inhibitors (tivantinib, cabozantinib, and crizotinib) and anti-MET antibodies (emibetuzumab and onartuzumab) are reported in the text.Conclusion: Emibetuzumab could be used for NSCLC cases with highMETexpression. Further, studies on onartuzumab failed to prove its efficacy, while the results of tivantinib trials were clinically but not statistically significant. Additionally, cabozantinib was effective, but adverse reactions were common, and crizotinib was generally well-tolerated.20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10216/131718eng2077-038310.3390/jcm9061918De Mello, RANeves, NMAmaral, GALippo, EGCastelo Branco, PDaniel PozzaTajima, CCAntoniou, Ginfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T13:17:21Zoai:repositorio-aberto.up.pt:10216/131718Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T23:37:37.505057Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
title The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
spellingShingle The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
De Mello, RA
Ciências da Saúde, Ciências médicas e da saúde
Health sciences, Medical and Health sciences
title_short The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
title_full The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
title_fullStr The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
title_full_unstemmed The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
title_sort The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
author De Mello, RA
author_facet De Mello, RA
Neves, NM
Amaral, GA
Lippo, EG
Castelo Branco, P
Daniel Pozza
Tajima, CC
Antoniou, G
author_role author
author2 Neves, NM
Amaral, GA
Lippo, EG
Castelo Branco, P
Daniel Pozza
Tajima, CC
Antoniou, G
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv De Mello, RA
Neves, NM
Amaral, GA
Lippo, EG
Castelo Branco, P
Daniel Pozza
Tajima, CC
Antoniou, G
dc.subject.por.fl_str_mv Ciências da Saúde, Ciências médicas e da saúde
Health sciences, Medical and Health sciences
topic Ciências da Saúde, Ciências médicas e da saúde
Health sciences, Medical and Health sciences
description Introduction: Non-small cell lung cancer (NSCLC) is the second most common cancer globally. The mesenchymal-epithelial transition (MET) proto-oncogene can be targeted in NSCLC patients.Methods: We performed a literature search on PubMed in December 2019 for studies on MET inhibitors and NSCLC. Phase II and III clinical trials published in English between 2014 and 2019 were selected.Results: Data on MET inhibitors (tivantinib, cabozantinib, and crizotinib) and anti-MET antibodies (emibetuzumab and onartuzumab) are reported in the text.Conclusion: Emibetuzumab could be used for NSCLC cases with highMETexpression. Further, studies on onartuzumab failed to prove its efficacy, while the results of tivantinib trials were clinically but not statistically significant. Additionally, cabozantinib was effective, but adverse reactions were common, and crizotinib was generally well-tolerated.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/131718
url https://hdl.handle.net/10216/131718
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2077-0383
10.3390/jcm9061918
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799135689502097408

Registros relacionados